INTRODUCTION {#S1}
============

Autism spectrum disorders (ASDs) are characterized by several cognitive and behavioral deficits that typically emerge during the second year of life ([@R41]; [@R62]). This distinctive developmental trajectory and selective degradation of particular motor and cognitive abilities suggest that ASDs arise from impaired developmental processes affecting the maturation of specific neural circuits. Recent evidence points to corticostriatal dysfunction as a common pathophysiology in ASDs ([@R13]). Imaging studies in multiple autistic cohorts revealed hypertrophy and abnormal functional connectivity of striatal and frontal cortical regions ([@R36], [@R37], [@R38]; [@R55]; [@R65]), and genomic and transcriptomic analyses have identified corticostriatal and striatal spiny projection neurons (SPNs) as neuronal populations with high expression of ASD risk genes ([@R5]; [@R64]). In addition, autistic individuals often present classical neurological signs of basal ganglia (BG) dysfunction such as cognitive inflexibility, dystonia, bradykinesia, and stereotypies ([@R13]; [@R51]).

Autism has a strong genetic basis and is associated with multiple *de novo* gene mutations and copy number variants (CNVs) ([@R14]). Several identified risk genes encode proteins involved in neuronal development and synaptogenesis ([@R45]; [@R49]), consistent with the early age of onset of ASDs ([@R62]). Accordingly, many mouse models harboring ASD-associated mutations exhibit deficits in synaptic and neural circuit function and behavioral phenotypes reminiscent of core symptoms of autism ([@R10]; [@R24]; [@R25]; [@R27]; [@R43]; [@R47]). However, longitudinal characterization of the neurobehavioral deficits in many of these animal models is still lacking ([@R9]), which, given the extensive molecular and circuit-level compensations occurring during brain development, precludes a conclusive estimate of the etiological significance of the different phenotypes observed at later developmental stages ([@R54]; [@R56]).

Haploinsufficiency of *SHANK3* is strongly associated with Phelan-McDermid syndrome (PMS) and idiopathic autism ([@R7]; [@R44]). SHANK3 belongs to the SHANK family of postsynaptic scaffolding proteins that integrate an extensive protein complex at glutamatergic synapses, where they interact with multiple synaptic channels and receptors ([@R24]). The deletion of exons 13--16 of *Shank3* in mice (*Shank3B*^−/−^) leads to several behavioral deficits, including hypolocomotion, abnormal social interactions, and repetitive and anxiety-like behaviors ([@R10]; [@R19]; [@R24]; [@R25]; [@R43]; [@R47]; [@R60]). Adult *Shank3B*^−/−^ mice have depressed corticostriatal transmission and altered patterns of cortical activity, potentially due to deficits in parvalbumin (PV) interneuron function ([@R10]; [@R15]; [@R19]; [@R47]). However, in contrast to adult stages, corticostriatal connectivity of *Shank3B*^−/−^ mice during early postnatal periods is increased compared to wild type (WT), suggesting that the loss of Shank3 induces a multiphasic developmental perturbation of striatal circuit connectivity and function ([@R48]). Whether postnatal perturbations of corticostriatal circuitry are concurrent with and causal of the onset of behavioral abnormalities in *Shank3B*^−/−^ mice remains unclear.

Here, we present a longitudinal behavioral characterization of *Shank3B*^−/−^ mice, showing that many of their behavioral deficits emerge during the second and third postnatal weeks. Proteomic analyses of striatal synaptic fractions show extensive synaptic remodeling during this period, with pronounced expression changes of several ASD risk factors. The normalization of excessive glutamatergic connectivity in neurons of the medial striatum of *Shank3B*^−/−^ mice by downregulating protein kinase A (PKA) activity during postnatal development reduces the severity of their phenotypes. These results suggest that disrupted postnatal development of striatal circuits is implicated in the onset of behavioral deficits in *Shank3B*^−/−^ mice and highlight the need to characterize the developmental trajectory of behavioral abnormalities in animal models of autism and other neurodevelopmental disorders to identify the primary patterns of circuit dysfunctionassociated with the emergence of maladaptive behaviors.

RESULTS {#S2}
=======

Early Onset of Behavioral Deficits in *Shank3B*^−/−^ Mice {#S3}
---------------------------------------------------------

To determine the developmental stage at which *Shank3B*^−/−^ mice begin manifesting behavioral deficits, we tested their performance in multiple behavioral assays across development (postnatal days \[P\] P15--P90). In the open field, *Shank3B*^−/−^ mice moved less compared to control WT littermates at all of the developmental ages tested, traversing less distance during the 30-min recording session ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}; mean ± SEM; P15--P90 WT: 20.1 ± 2, 26.4 ± 2, 29.6 ± 2.5, 36.9 ± 3.1, 32.1 ± 2.8 m; *Shank3B*^−/−^: 9.0 ± 1.3, 14.6 ± 1.8, 17.5 ± 1.4, 25.3 ± 3, 22.2 ± 1.9 m, n = 10,13; repeated measures ANOVA \[RMANOVA\] with Bonferroni multiple comparison test \*p \< 0.05, \*\*p \< 0.005, \*\*\*p \< 0.001). Moreover, *Shank3B*^−/−^ animals explored the center of the arena less compared to WT after P21 and spent less time in the center of arena at P15 ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}; mean ± SEM; total distance in center of arena P15--P90 WT: 4.4 ± 0.7, 6.3 ± 0.9, 6.1 ± 0.9, 12.7 ± 1.7, 11.3 ± 1.8 m; *Shank3B*^−/−^: 1.3 ± 0.2, 2.4 ± 0.5, 2.3 ± 0.3, 6.8 ± 1.0, 5.7 ± 0.7 m, n = 10,13; RMANOVA with Bonferroni multiple comparison test \*p \< 0.05, \*\*\*p \< 0.001; mean ± SEM center/arena time P15--P90 WT: 0.07 ± 0.01, 0.14 ± 0.03, 0.14 ± 0.02, 0.47 ± 0.12, 0.45 ± 0.12 m; *Shank3B*^−/−^: 0.02 ± 0.01, 0.07 ± 0.02, 0.06 ± 0.01, 0.23 ± 0.05, 0.22 ± 0.05, n = 10,13, RMANOVA with Bonferroni multiple comparison test \*p \< 0.05). Reduced rearing of *Shank3B*^−/−^ mice in relation to WT was observed at P15--P60 and became similar between genotypes at P90 ([Figure 1E](#F1){ref-type="fig"}; mean ± SEM; wall rearing bouts per session P15--P90 WT: 43.6 ± 5.8, 61.2 ± 6.4, 56.6 ± 4.9, 69.3 ± 11.9, 45.8 ± 8.33 bouts; *Shank3B*^−/−^: 18 ± 3.5, 37 ± 7.2, 31.4 ± 3.2, 42.17 ± 8.9, 32.2 ± 4.5 bouts, n = 10,13; RMANOVA with Bonferroni multiple comparison test \*p \< 0.05). Consistent with previous reports, *Shank3B*^−/−^ mice groomed for longer periods, although increased grooming only emerged during the P15--P21 stage, when the maximal phenotypic difference across genotypes was reached ([Figure 1G](#F1){ref-type="fig"}; mean ± SEM; total grooming time P15--P90 WT: 418.6 ± 34.5, 363.4 ± 45.3, 319.5 ± 63.8, 238.2 ± 50.6, 190.6 ± 45.2 s; *Shank3B*^−/−^: 497.7 ± 72.9, 730.2 ± 59.8, 567.8 ± 47, 433.1 ± 63.7, 324.3 ± 56.6 s, n = 10,13; RMANOVA with Bonferroni multiple comparison test \*p \< 0.05, \*\*\*p \< 0.001). The increase in total grooming time occurred predominantly due to longer duration of individual grooming bouts, which remained similar in number across groups ([Figures 1G](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}; mean ± SEM; average groom bout duration P15--P90 WT: 63.6 ± 8.3, 64.3 ± 7.2, 43.5 ± 6.5, 24.1 ± 3.3, 30 ± 3.7 s; *Shank3B*^−/−^: 69.6 ± 9.2, 96.4 ± 9.1, 62.4 ± 6.4, 52.6 ± 12.3, 64.6 ± 6.9 s, n = 10,13; grooming bouts per 30-min session P15--P90 WT: 7.05 ± 0.57, 6.05 ± 0.74, 8.7 ± 2.09, 9.25 ± 1.53, 6.0 ± 1.33 bouts; *Shank3B*^−/−^: 7.19 ± 1.2, 8.39 ± 0.56, 10.65 ± 1.39, 10.33 ± 1.13, 5.46 ± 0.67 bouts, n = 10,13; RMANOVA with Bonferroni multiple comparison test \*p \< 0.05). No sex dimorphism was observed in the open field tests as both male and female *Shank3B*^−/−^ mice exhibited similar behavioral trends compared to WT ([Figure S1](#SD1){ref-type="supplementary-material"}), which is consistent with previous findings ([@R25]). In addition, the performance of *Shank3B*^−/−^ mice in the accelerating rotarod was worse compared to WT at P17--P20 ([Figure 1I](#F1){ref-type="fig"}; mean ± SEM; time to fall in seconds P17 WT: 60.5 ± 8.6, 72.4 ± 9.1, 80.5 ± 13.4; *Shank3B*^−/−^: 37.1 ± 9, 54.8 ± 9.6, 49.9 ± 7.8; P18 WT: 76.6 ± 11, 99.6 ± 12.9, 114.6 ± 10.8; *Shank3B*^−/−^: 53.7 ± 7.7, 63.8 ± 12.1, 66.3 ± 11.7; P19 WT: 97.5 ± 11.1, 141 ± 18.3, 122.6 ± 12.4; *Shank3B*^−/−^: 71.8 ± 9, 84.2 ± 10.5, 88.9 ± 10.2; P20 WT: 113.2 ± 22.4, 151.9 ± 17.2, 172.6 ± 23.2; *Shank3B*^−/−^: 79.8 ± 9.2, 100.8 ± 16.1, 107.3 ± 14.6, n = 10,15; RMANOVA Fisher's least significant difference \[LSD\] test \*p \< 0.05, \*\*p \< 0.005, \*\*\*p \< 0.0005). Thus, behavioral abnormalities in *Shank3B*^−/−^ begin during early post-natal development, a period during which extensive activity-dependent striatal circuit remodeling occurs.

Dynamic Regulation of the Striatal Synaptic Proteome during Postnatal Development {#S4}
---------------------------------------------------------------------------------

To gain insight into the molecular mechanisms and signaling pathways regulating the postnatal maturation of striatal circuits, we analyzed synaptosomal fractions of the dorsal striatum of P8--P18 mice by liquid chromatography-tandem mass spectrometry (LC-MS/MS) ([Figure 2](#F2){ref-type="fig"}). The biochemical isolation of synaptosomes enriched synaptic proteins ([Figure S2](#SD1){ref-type="supplementary-material"}) and permitted the identification of 7,405 protein species that exhibited different expression patterns across development ([Figures 2A](#F2){ref-type="fig"}--[2C](#F2){ref-type="fig"}; [Data S1](#SD1){ref-type="supplementary-material"}). The relative abundance of several markers of synaptic and neuronal maturation such as doublecortin (DCX), synaptic vesicle glycoprotein 2 (SV2A), postsynaptic density protein 95 (PSD95), Ca^2+^/calmodulin-dependent protein kinase IIα (CaMKIIα), excitatory amino acid transporter 2 (EAAT2), and the myelin-associated enzyme 2′,3′-cyclic nucleotide 3′ phosphodiesterase (Cnp) changed markedly during this developmental period ([Figures 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}), consistent with previous reports ([@R17]). An intra-sample comparison across development identified a cluster of 142 proteins with significant changes in relative abundance during P8--P18 ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}; p \< 0.001, Friedman test with Benjamini-Hochberg multiple test correction with p \< 0.001), 92 of which formed a highly interconnected network defined by protein-protein interactions ([Figure 2D](#F2){ref-type="fig"}). Notably, 35 of these proteins are encoded by ASD risk genes and 28 others are homologs of other identified risk alleles ([https://gene.sfari.org](https://gene.sfari.org/)), pointing to a high degree of functional convergence and interaction of many ASD risk factors during this stage of striatal development. Furthermore, regulatory and catalytic subunits of cyclic AMP (cAMP)-dependent PKA and modulators of PKA activity are dynamically regulated during this period ([Figures 2F](#F2){ref-type="fig"}--[2I](#F2){ref-type="fig"}), with a progressive reduction in the synaptic levels of PKA subunits and of several A-kinase anchoring proteins (AKAPs), similar to what is observed in developing cortical circuits ([@R17]) and consistent with the altered regulation of PKA signaling during this period of striatal maturation ([@R31]; [@R67]; [@R68]). These results point to an extensive remodeling of the striatal synaptic proteome during this developmental period, which is consistent with ongoing neuronal maturation and synaptogenesis.

Developmental Switch in SPN Adaptation to Cortical Hyperactivity {#S5}
----------------------------------------------------------------

Compared to WT controls, *Shank3B*^−/−^ SPNs have an elevated frequency of miniature excitatory postsynaptic currents (mEPSCs) at P14, suggesting an increase in the number, or accelerated maturation, of excitatory synapses ([@R48]). However, in adult stages, this phenotype is reversed, and corticostriatal transmission and connectivity are reduced ([@R47]; [@R61]). The extensive postnatal changes in striatal synaptic composition suggested that these two phenotypes could be due to distinct plasticity mechanisms induced by elevated cortical activity in developing and mature SPNs. To test this hypothesis, we recorded mEPSCs in SPNs after different periods of cortical hyperactivity induced across development ([Figure 3](#F3){ref-type="fig"}). To increase cortical activity, we blocked synaptic GABA release from cortical interneurons by conditional deletion of the vesicular GABA transporter (VGAT) in *Slc32a1*^*f/f*^ transgenic mice ([@R48]). Unilateral injection of adeno-associated viruses (AAVs) expressing Cre recombinase under control of the neuron-specific synapsin promoter (AAV-Syn-Cre-EGFP) allowed restricted Cre recombination in neurons of the anterior cingulate cortex (ACC), a major source of corticostriatal projections to dorsomedial striatum (DMS) ([Figure 3A](#F3){ref-type="fig"}). Mice were injected at P8 to improve stereotaxic precision and avoid disrupting GABA-mediated developmental processes during the first postnatal week. AAV-Syn-EGFP injections were used as controls. Whole-cell recordings of DMS SPNs at P14 (7 days post-injection) revealed that cortical hyperactivity during P8--P14 significantly increased SPN mEPSC frequency ([Figure 3B](#F3){ref-type="fig"}; mean ± SEM; SPN mEPSC frequency P14, GFP 0.71 ± 0.07 Hz; Cre 1.39 ± 0.16 Hz, n = 27,26 neurons from 4 mouse pairs, unpaired Mann-Whitney test p = 0.0002) and mEPSC amplitude ([Figure 3C](#F3){ref-type="fig"}; mean ± SEM; SPN mEPSC amplitude P14, GFP 18.41 ± 0.59 pA; Cre 20.93 ± 0.82 Hz, unpaired Mann-Whitney test p = 0.039). However, VGAT deletion from P8 to P60 resulted in a reversed phenotype such that the SPN mEPSC frequency of AAV-Cre-EGFP mice was reduced compared to controls ([Figure 3D](#F3){ref-type="fig"}; mean ± SEM; SPN mEPSC frequency P60, GFP 2.37 ± 0.25 Hz; Cre 1.89 ± 0.20 Hz, n = 52, 54 neurons from 5 mouse pairs, Mann-Whitney test p = 0.033). mEPSC amplitude remained elevated compared to SPNs in AAV-GFP-injected control mice ([Figure 3E](#F3){ref-type="fig"}; mean ± SEM; SPN mEPSC amplitude P60, GFP 14.66 ± 0.33 pA; Cre 15.97 ± 0.43 Hz, unpaired Mann-Whitney test p = 0.036).

To identify at which developmental stage cortical hyperactivity starts inducing a reduction in SPN mEPSC frequency, we performed similar experiments manipulating cortical activity at different developmental time points ([Figure 3E](#F3){ref-type="fig"}). In contrast to injections at P8, injections of AAV-Cre at P15, P21, or P53 resulted in a lower mEPSC frequency 7 days post-injection ([Figures 3F](#F3){ref-type="fig"}--[3H](#F3){ref-type="fig"}, left plot; mean ± SEM; SPN mEPSC frequency P15--P21 GFP 3.64 ± 0.46 Hz; Cre 2.29 ± 0.26 Hz, n = 18,19 neurons from 3 mouse pairs; P21--P28 GFP 4.46 ± 0.74 Hz; Cre 2.5 ± 0.35 Hz, n = 18,18 neurons from 3 mouse pairs; P53--P60 GFP 2.75 ± 0.25 Hz; Cre 1.92 ± 0.20 Hz, n = 30,30 neurons from 4 mouse pairs; Mann-Whitney test \*p \< 0.05, \*\*p \< 0.01) with an increase in mEPSC amplitude observed only in the P53--P60 group ([Figures 3F](#F3){ref-type="fig"}--[3H](#F3){ref-type="fig"}, right plot; mean ± SEM; SPN mEPSC amplitude: P15--P21 GFP 14.79 ± 0.33 pA; Cre 14.75 ± 0.38 Hz, n = 18,17 neurons from 3 mouse pairs; P21--P28 GFP 15.29 ± 0.59 pA; Cre 14.83 ± 0.36 Hz, n = 18,18 neurons from 3 mouse pairs; P53--P60 GFP 13.28 ± 0.21 pA; Cre 14.27 ± 0.33 Hz, n = 30,30 neurons from 4 mouse pairs, unpaired Mann-Whitney test \*p \< 0.05). There was no significant difference in the pair-pulse ratio (PPR) of electrically evoked EPSCs (eEPSC) in SPNs of AAV-Cre-EGFP-injected animals at P53 compared to AAV-GFP-injected controls ([Figures 3K](#F3){ref-type="fig"} and [3L](#F3){ref-type="fig"}; mean ± SEM; eEPSC PPR, AAV-GFP 1.09 ± 0.04; AAV-Cre-EGFP 1.01 ± 0.07, n = 14,12 neurons from 3 mouse pairs, unpaired t test p = 0.37), suggesting the decrease in mEPSC frequency is likely not caused by lower vesicular release probability. These results indicate that cortical hyperactivity induces distinct forms of synaptic plasticity in developing and mature SPNs, consistent with previous *ex vivo* studies in acute slices ([@R46]).

PKA Inhibition in SPNs during Postnatal Development Reduces Corticostriatal Connectivity {#S6}
----------------------------------------------------------------------------------------

Postnatal maturation of glutamatergic synapses in SPNs is regulated by PKA activity ([@R31]), but whether postsynaptic PKA signaling is required for this process remains unclear. To address this, we infected the striata of P8 mice with AAVs expressing protein kinase inhibitor peptide (PKIα) under the neuron-specific synapsin promoter (AAV8-hSyn-PKIα-IRES-mRuby2 \[internal ribosome entry site, IRES\]) and performed whole-cell recording in PKIα^+^ and neighboring uninfected SPNs 7 days post-injection ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). PKIα expression decreased the SPN mEPSC frequency ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}; mean ± SEM; control SPN 1.28 ± 0.17 Hz, PKIα SPN 0.64 ± 0.07 Hz, n = 19,23 neurons from 5 mice, unpaired Mann-Whitney test p = 0.001), with no significant change in mEPSC amplitude ([Figures 3C](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}; mean ± SEM; control SPN 14.5 ± 0.5 pA, PKIα SPN 13.9 ± 0.4 pA, n = 19,23 neurons from 5 mice, unpaired Mann-Whitney test p = 0.21). PKIα expression increased SPN input resistance (R~i~) and induced a small reduction in membrane capacitance ([Figure S3](#SD1){ref-type="supplementary-material"}; mean ± SEM; R~i~: control SPN 173.2 ± 15.52 MΩ; PKIα SPN 315.7 ± 27.49 MΩ; unpaired Mann-Whitney test p \< 0.0001; membrane capacitance: control SPN 51.3 ± 2.3 pF; PKIα SPN 47.5 ± 2.2 pF, n = 19,23 neurons from 5 mice). To determine whether PKIα expression specifically reduces corticostriatal connectivity, we compared optogenetically evoked postsynaptic currents (oEPSC) in PKIα^+^ and control SPNs of *Rbp4-Cre;Ai32* (*Rbp4-Cre;ChR2*^*f/f*^) transgenic mice that express Cre recombinase under the retinal binding protein 4 (Rbp4) promoter, restricting channelrhodopsin-2 (ChR2) expression predominantly to layer 5 cortical neurons ([Figure 4E](#F4){ref-type="fig"}). The optical stimulation of ChR2^+^ fibers in DMS was induced by 1-ms pulses of 473 nm light delivered through the objective while performing voltage-clamp whole-cell recordings in SPNs. α-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)-type and *N*-methyl-[D]{.smallcaps}-aspartate (NMDA)-type glutamate receptor-mediated currents were isolated by inhibiting GABA~A~ receptors and recording at holding potentials (V~h~) of −70 and +40 mV, respectively. The expression of PKIα from P8 to P14 strongly reduced Rbp4^+^ AMPA receptor (AMPAR) oEPSC amplitude ([Figures 4F](#F4){ref-type="fig"} and [4G](#F4){ref-type="fig"}; mean ± SEM; control −956.1 ± 187.9; PKIα −416 ± 84.7 pA; n = 13,16 neurons from 3 mice, unpaired Mann-Whitney test p = 0.013) without a significant change in the NMDAR/AMPAR current amplitude ratio ([Figure 4H](#F4){ref-type="fig"}; mean ± SEM; control 1.42 ± 0.16; PKIα 1.55 ± 0.15; n = 9,10 neurons from 3 mice, unpaired Mann-Whitney test p = 0.28).

Postnatal Expression of PKIα in DMS Neurons Ameliorates Behavioral Abnormalities in *Shank3B*^−/−^ Mice {#S7}
-------------------------------------------------------------------------------------------------------

Repeated corticostriatal stimulation in ventromedial striatum generates persistent overgrooming in mice ([@R1]), whereas reduction of corticostriatal connectivity in individuals with obsessive-compulsive disorder (OCD) significantly improves compulsive behaviors ([@R12]). Moreover, focal disinhibition of striatal circuits in mice causes dystonia and motor stereotypies ([@R3]; [@R22]), suggesting that hyperactivity of striatal circuits may underlie core behavioral deficits in ASDs ([@R13]). Given the critical role of PKA in regulating SPN glutamatergic synapse maturation ([@R31]), we tested whether reducing the excessive postnatal striatal connectivity found in *Shank3B*^−/−^ mice by postsynaptic inhibition of PKA would decrease the severity of their behavioral deficits. We expressed PKIα in medial striatal neurons from P8 to P21 by injecting AAV8-hSyn-PKIα-IRES-mRuby2 ([@R6]; [@R39]) and compared behavioral performance with control AAV-GFP-injected littermates at P21. As observed in WT SPNs, expression of PKIα in *Shank3B*^−/−^ SPNs during postnatal development reduces both mEPSC frequency ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}; mean ± SEM; control 1.54 ± 0.14 Hz; PKIα 0.51 ± 0.09 Hz; n = 17,16, unpaired Mann-Whitney test p \< 0.0001) and amplitude ([Figure 5C](#F5){ref-type="fig"}; mean ± SEM; control 13.9 ± 0.3 pA; PKIα 12.7 ± 0.4 pA; n = 17,16 neurons from 3 mouse pairs, unpaired Mann-Whitney test p = −0.023). Expression of PKIα in medial striatum had a profound impact on behavior, resulting in overall decreased grooming time and grooming bout duration ([Figures 5D](#F5){ref-type="fig"}--[5G](#F5){ref-type="fig"}; mean ± SEM; total grooming time: control 481.8 ± 62, PKIα 320.4 ± 34 s; groom bout duration: control 108.4 ± 14.5, PKIα 76.2 ± 5.8 s; groom bout number per session: control 4.9 ± 0.5, PKIα 4.2 ± 0.4; n = 16,16 mice, unpaired t test \*p \< 0.05). Moreover, striatal PKIα expression increased locomotor activity, increasing the distance traversed in total and in the arena center, as well as the number of wall rearings ([Figures 5H](#F5){ref-type="fig"}--[5L](#F5){ref-type="fig"}; mean ± SEM; total distance in arena: control 14.9 ± 1.7, PKIα 25 ± 2.5 m; center:arena distance ratio: control 0.19 ± 0.02, PKIα 0.24 ± 0.01; total time spent in center of arena: control 188.4 ± 39.5, PKIα 0.24 ± 0.01; number of wall rearings per session: control 37.9 ± 4.2, PKIα 64.8 ± 7.8; n = 16,16 mice, unpaired t test \*p \< 0.05, \*\*p \< 0.005), both metrics being associated with increased exploratory activity and reduced anxiety in mice. By contrast, PKIα expression in the medial striatum of WT mice had no influence on animal behavior in the open field ([Figure S4](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S8}
==========

Despite increasing knowledge of the genetic underpinnings of autism risk, the specific neural substrates and pathophysiological mechanisms underlying the emergence of motor and cognitive deficits in ASDs remain unclear. Studies in transgenic mouse models have begun to address how different genetic mutations associated with ASDs disrupt neuron physiology, circuit organization, and animal behavior ([@R13]; [@R27]). However, many of these studies often focused on the characterization of adult animals, which, given the extensive molecular and circuit-level adaptations occurring during brain development, limits our understanding of the etiological significance of the phenotypes observed during these adult stages ([@R54]; [@R56]). Here, by longitudinally tracking mouse behavior, we found that several of the behavioral deficits previously reported in adult *Shank3B*^−/−^ mice are already observed at P15--P21. This early onset indicates that the relevant pathogenic processes implicated in the emergence of maladaptive behaviors in these mice occur either during or before this developmental stage. Notably, the \~P12--P14 period of brain maturation in the mouse is homologous to the \~1--2 years of human development ([@R50]), which is the typical age of symptom onset in ASDs. The emergence of behavioral deficits during this particular period strengthens the face validity of *Shank3B*^−/−^ mice as a model system of ASD pathogenesis and highlights the need to characterize early postnatal circuit maturation in mouse models of autism and other neurodevelopmental disorders to distinguish primary pathophysiological mechanisms from secondary developmental adaptations.

Whereas deficits in locomotor and exploratory behavior in *Shank3B*^−/−^ mice were observed as early as P15, overgrooming only emerged during P15--P21. This slightly delayed onset is consistent with previous reports showing unaltered grooming patterns of *Shank3B*^−/−^ mice at P15 ([@R25]) and indicates that this maladaptive behavioral pattern is established during the third postnatal week, a period of extensive functional maturation of striatal circuits ([@R48]; [@R53]). Moreover, this developmental trajectory of overgrooming resembles the gradual emergence of repetitive and ritualistic patterns of behavior in autistic children during the first years of life ([@R16]; [@R66]) and may account for the conflicting reports of the extent of overgrooming in *Shank3B*^−/−^ mice across different studies ([@R10]; [@R25]; [@R47]). By contrast, the early onset of hypolocomotion in *Shank3B*^−/−^ mice is consistent with the observed hypotonia in infants diagnosed with PMS ([@R7]). However, no early deficits in geotaxis were found in *Shank3B*^−/−^ pups during the first 2 postnatal weeks, suggesting that this early phenotype is likely due to central and not peripheral motor deficits ([@R25]). In addition, we observed no sexual dimorphism in the behavior of \<P21 *Shank3B*^−/−^ mice, which is consistent with previous reports ([@R25]) and potentially due to sexual immaturity.

Proteomic analysis of striatal synaptosome fractions revealed extensive remodeling of synaptic protein composition from P8 to P18 ([Figure 2](#F2){ref-type="fig"}). The expression of DCX, a microtubule-associated protein involved in dendritic growth that is downregulated as synaptic connectivity is stabilized ([@R11]), decreased markedly during this period, consistent with the extensive activity-dependent maturation of striatal synapses ([@R48]). Of the 140 proteins with the most pronounced developmental expression changes, 92 form a cluster of identified protein-protein interactions. Notably, 35 of the 92 are products of identified ASD risk genes and 28 others of closely related homologs. These results point to convergent and dynamic regulation of several ASD risk factors during this particular period of striatal development, which may have important implications for understanding how genetic variants of limited penetrance interact and contribute to ASD pathogenesis ([@R14]; [@R29]). Furthermore, we detected a developmental reduction in both the catalytic and regulatory subunits of PKA and an increase in the negative regulators of PKA activity from P8 to P18, suggesting a change in PKA signaling regulation during this period. Induction of long-term potentiation (LTP) in hippocampal CA3-CA1 synapses is PKA dependent before but not after P14 ([@R68]), whereas mice lacking the PKA regulatory subunit Prkar2b show impaired hippocampal LTP at P10--P14 but not P21--P28 ([@R67]). Our data show a pronounced reduction in Prkar2b expression in striatal synapses from P8 to P18, and in AKAPs that bind and recruit Prkar2b such as AKAP12 ([@R20]) and the ASD-associated neurobeachin ([@R58]). Moreover, we have previously shown that *in vivo* systemic administration of PKA inhibitor H89 abrogates the activity-dependent potentiation of SPN corticostriatal synapses at P8--P9 ([@R31]), suggesting a critical role for PKA signaling in early SPN synaptic plasticity. In addition, caged-glutamate-induced spinogenesis in both striatal SPN and cortical pyramidal neurons is also blocked by H89 and shows a progressive developmental decrease in induction efficiency up to \~P18, after which point it is no longer inducible ([@R31]; [@R34]). Here, we extend these results and show that the postsynaptic inhibition of PKA in SPNs during P8--P15 greatly reduces corticostriatal transmission. PKIα expressing SPNs also exhibited higher membrane resistance, suggesting that PKA signaling may also regulate the maturation of SPN-intrinsic properties, which is consistent with the dopamine-dependent maturation of SPN excitability described recently ([@R40]).

In *Shank3B*^−/−^ mice corticostriatal connectivity is increased during postnatal development and decreased during adult stages ([@R47]; [@R48]; [@R61]). The mechanisms underlying this biphasic developmental trajectory remain unclear, but reducing cortical activity during early postnatal periods in *Shank3B*^−/−^ mice normalizes the number of excitatory synapses onto SPNs. The loss of Shank3 also increases cortical ([@R10]) and striatal ([@R60]) activity during adult stages and upregulates the expression and post-translational processing of activity-dependent proteins such as P-CREB ([@R2]). Based on this evidence, we hypothesized that the different SPN mESPC phenotypes observed in young and adult *Shank3B*^−/−^ mice may reflect distinct adaptations of these neurons to cortical hyperactivity during different developmental periods. Consistent with this idea, both chronic and transient elevations of cortical activity during adulthood decrease SPN mEPSC frequency ([Figures 3D](#F3){ref-type="fig"} and [3H](#F3){ref-type="fig"}). This reduction in glutamatergic transmission in response to elevated cortical activity is in line with the induction of long-term depression (LTD) of striatal synapses by high-frequency stimulation (HFS) in *ex vivo* slice preparations ([@R33]). This potential mechanism may also explain why the overall decrease in mEPSC frequency observed in adult *Shank3B*^−/−^ SPNs is predominantly due to the loss of inputs in striatopallidal SPNs ([@R61]), as some studies reported more robust induction of HFS-LTD in this subclass of SPNs compared to striatonigral SPNs ([@R33]). Nevertheless, we found that increased cortical activity before \~P15 increases SPN mEPSC frequency instead ([Figure 3I](#F3){ref-type="fig"}). This developmental switch is consistent with the transition from HFS-induced LTP to LTD in rat corticostriatal synapses *ex vivo* at \~P15--P16 ([@R46]) and may underlie the distinct SPN mEPSC phenotypes observed in developing versus adult *Shank3B*^−/−^ mice. The mechanisms underlying these different developmental responses remain unclear, but developmental changes in synaptic composition, intrinsic excitability, and neuromodulatory signals ([@R31]; [@R40]; [@R48]; [@R53]; [@R8]; [@R32]) may alter spike-timing-dependent plasticity rules in corticostriatal synapses, similar to what is observed during the development of cortical circuits ([@R28]).

Postsynaptic expression of PKIα in striatal neurons during postnatal development ameliorated the severity of multiple behavioral deficits in *Shank3B*^−/−^ mice. It is important to note that adult restoration of Shank3 expression or chemogenetic increase of striatopallidal SPN excitability in *Shank3B*^−/−^ mice can also normalize some abnormal behaviors such as over-grooming ([@R43]; [@R61]). However, such manipulations had no effect on hypolocomotion and rearing, two of the most robust and replicable phenotypes in *Shank3* knockout (KO) animals ([@R10]; [@R25]; [@R43]; [@R47]; [@R60]). The strategy reported here is, to our knowledge, the first manipulation that effectively improved these behavioral parameters in *Shank3B*^−/−^ mice. It will be important for future studies to identify the specific patterns of striatal circuit malformation induced by early cortical hyperactivity and to address whether early insults during this postnatal period result in irreversible circuit dysfunction. The increased activity of medial striatal circuits is associated with overgrooming in mice ([@R1]; [@R4]), and structural and functional deficits between frontal cortical regions and DMS have been found in multiple autistic individuals ([@R36], [@R37], [@R38]; [@R55]; [@R65]). The behavioral improvements observed in response to PKIα expression in medial striatum may thus be due to a reduction in frontal cortical-DMS corticostriatal activity or connectivity. However, it is important to note that medial striatal regions also receive extensive inputs from the thalamus, the basolateral amygdala (BLA), and the bed nucleus of the stria terminalis (BNST) ([@R35]; [@R52]; [@R57]). Although it remains unclear how the development of these subcortical projection systems is regulated by early neural activity, the positive effect of PKIα expression may be due to the downregulation of these inputs. Alternatively, a net reduction in the excitatory drive into medial SPN populations may normalize the activity converging onto BG output nuclei and allow for proper integration of sensorimotor information processed by lateral striatal circuits ([@R21]; [@R51]). Indeed, excessive BG activity is associated with motor deficits in numerous movement disorders ([@R63]), and surgical ablation of BG output nuclei often results in marked behavioral improvements in some of these conditions ([@R42]). By contrast, no available treatments exist for ASDs and all of the clinical trials performed to date have had minimal success ([@R23]). PKA activity is modulated by a myriad of upstream signaling pathways that are differentially expressed and regulated in different neuronal populations across development ([@R18]). The modulation of PKA signaling thus offers the potential for cell-type-specific tuning of synaptogenesis, providing a potential avenue for correcting the abnormal developmental trajectories of striatal circuits in neurodevelopmental disorders with early imbalances in neural activity.

STAR★METHODS {#S9}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S10}
=======================================

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rui Peixoto (<rup14@pitt.edu>). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S11}
======================================

All experimental manipulations on mice were performed in accordance with protocols approved by the Harvard Standing Committee on Animal Care and guidelines described in the US National Institutes of Health *Guide for the Care and Use of Laboratory Animals*. Mice were housed on a 12/12hr light/dark cycle with chow and water provided *ad libitum*. Mice were weaned at P21--23 and separated by sex in cages of 2--4 animals of mixed genotypes. For electrophysiology studies, *Rbp4*-Cre transgenic mice (GENSAT \#RP24--285K21) were bred to conditional channelrhodopsin-2 (ChR2) expressing mice expressing ChR2(H134R)-EYFP under control of an upstream loxP-flanked STOP cassette (Ai32; referred to as *ChR2*^*f/f*^; The Jackson Laboratory \#012569). For conditional deletion of the vesicular GABA transporter in cortical cells we used *Slc32a1*^*f/f*^ mice (The Jackson Laboratory \#012897). Shank3B^−/−^ knock-out mutant mice were described previously ([@R47]) and obtained from The Jackson Laboratory (\#017688). Longitudinal characterization of Shank3B^−/−^ mouse behavior was performed in age-matched littermates from breeding pairs of Shank3B^+/−^ heterozygous animals. For PKIα rescue experiments described in [Figure 5](#F5){ref-type="fig"} Shank3B^−/−^ mice were bred in a homozygous scheme to increase cohort size. Mixed cohorts of male and female mice were used in all experiments as no sexual dimorphism was ever detected in the mouse lines used and behavioral assays tested ([Figure S1](#SD1){ref-type="supplementary-material"}) as reported in previous studies ([@R25]).

METHOD DETAILS {#S12}
==============

Behavioral assays {#S13}
-----------------

For all behavioral assays, mice were habituated to the test room for at least one hour prior to experiments. For tests in pre-weaned mice (P15-P21) the cage with the dam and the litter was taken to the testing room where pups were taken out of the cage and placed in a new cage with water and food available until all pups were tested. Dams remained in the home cage for the duration of the experiment. Open field test was performed in a 22×22cm plexiglass chamber with white opaque walls (center of arena - 13×13cm inner region). Uniform illumination was kept consistent across experiments with 1500lux 5500k diffused light (Genaray Octalux OLED-55). Behavior was video recorded with a CCD camera (Thorlabs DCU22M) at 22fps using Thorcam software.

Stereotaxic intracranial injections {#S14}
-----------------------------------

Intracranial injections were performed in P8, P15, P21 or P53 mice anesthetized with isoflurane placed into a stereotaxic apparatus (Kopf Instruments model 1900). Viruses were delivered by injecting 50--200nl at a maximum rate of 100 nl/min using a Harvard Apparatus PHD ULTRA CP injector. For deletion of VGAT in cortical neurons, virus expressing Cre-EGFP under the neuron specific Synapsin promoter (AAV9-hSyn-Cre-EGFP, Penn vector core AV-9-PV1848) were injected in *Slc32a1*^*f/f*^ mice using coordinates: AP +1.5 mm; ML +0.6 mm; Depth −1 mm from dura. For PKIα infection of striatal neurons, WT and Shank3B^−/−^ P8 mice were injected bilaterally with AAV8-hSyn-PKI-ires-mRuby or AAV9-hSyn-EGFP (Penn vector core AV-9-PV1696) using the following coordinates: AP +0.5 mm; ML +1.25 mm; Depth −2.5 mm from dura. Following injections and wound closure, mice received ketoprofen for analgesia and were returned to home cages for at least 7 days. Injection sites and viral expression were confirmed post hoc by whole brain sectioning and imaging and mice with erroneous injections were discarded from analysis.

Acute slice preparation and electrophysiology {#S15}
---------------------------------------------

Acute brain slices and whole-cell recordings from SPNs were performed using standard methods as described previously ([@R30]). Briefly, mice (6--60 days old) were anesthetized by isofluorane inhalation and perfused transcardially with ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO~3~, 2 CaCl~2~, 1 MgCl~2~, 1.25 NaH~2~PO~4~ and 25 glucose (310 mOsm per kg). Cerebral hemispheres were removed and sliced in cold ACSF (275um coronal slices in Leica VT1200S vibratome). Coronal slices containing striatum were recovered for 15--20 minutes at 34°C in choline-based recovery solution (in mM): 110 choline chloride, 25 NaHCO3, 2.5 KCl, 7 MgCl2, 0.5 CaCl2, 1.25 NaH2PO4, 25 glucose, 11.6 ascorbic acid, and 3.1 pyruvic acid), and then transferred to a holding chamber with 34°C ACSF that progressively cooled down to room temperature (20--22°C). All recordings were obtained within 1--6 h after slicing and solutions were constantly bubbled with 95% O2/5% CO2. Individual slices were transferred to a recording chamber mounted on an upright microscope (Olympus BX51WI) and continuously perfused (1--2 mL per minute) with ACSF at room temperature. Cells were visualized using a 40 × water-immersion objective with infrared DIC optics. Whole-cell voltage-clamp recordings were made from SPNs in dorsomedial regions of striatum. Patch pipettes (2--4 MU) pulled from borosilicate glass (BF150--86-7.5, Sutter Instruments) were filled with a Cs^+^-based internal solution containing (in mM): 130 CsMeSO~4~, 10 HEPES, 1.8 MgCl~2~, 4 Na~2~ATP, 0.3 NaGTP, and 8 Na~2~-phosphocreatine, 10 CsCl~2~, 3.3 QX-314 (Cl^−^ salt), (pH 7.3 adjusted with CsOH; 295 mOsm per kg). For all voltage-clamp experiments, errors due to voltage drop across the series resistance (\< 20 MΩ) were left uncompensated. In all experiments, GABAR currents were blocked with 20 μM SR95531 hydrobromide to block inhibition from local interneuron or SPNs collaterals. For optogenetic light-evoked AMPAR oEPSC recordings ACSF contained 10 μM (R)-CPP to block NMDA currents and recordings were performed at −70 mV holding potential. For mEPSC recordings, ACSF also included 1 μM TTX. Voltage-clamp recordings were performed at room temperature (20--22°C). To activate ChR2-expressing neuronal fibers, light from a 473 nm laser (Opto engine LLC) was focused on the back aperture of the microscope objective to produce wide-field illumination of the recorded cell. TTL triggered pulses of light (1 ms duration; 6 mW/mm^2^ under the objective) were delivered at the recording site at 30 s inter-stimulus intervals. To calculate paired-pulse ratio (PPR), recordings were performed in current-clamp mode using a K^+^ based low chloride internal solution composed of (in mM) 130 KMeSO3, 3 KCl, 10 HEPES, 1 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 8Na2-phosphocreatine (pH 7.3 adjusted with KOH; 295 mOsm). Current-clamp recordings were perfomed at 32°C and electrical stimulation was performed with bipolar tungsten electrodes inserted in the callosal tract dorsal to DMS. Membrane currents and potentials were amplified and low-pass filtered at 3 kHz using Multiclamp 700B amplifier (Molecular Devices), digitized at 10 kHz and acquired using National Instruments acquisition boards and a custom version of ScanImage written in MATLAB (Mathworks).

Brain tissue processing and imaging {#S16}
-----------------------------------

Mice were deeply anesthetized with isofluorane and perfused transcardially with 4% paraformaldehyde in 0.1 M sodium phosphate buffer. Brains were fixed for 24 hours at 4°C, washed in phosphate buffer saline (PBS) and sectioned (50 μm) coronally using a vibratome (Leica VT1000s). Brain sections were mounted on glass slides, dried and mounted with ProLong antifade reagent containing DAPI (Molecular Probes). Whole brain sections were imaged with an Olympus VS110 slide-scanning microscope.

Biochemical isolation of synaptosomes {#S17}
-------------------------------------

Mice of different ages were anesthetized with isoflurane and perfused with ice cold Hank's Balanced Salt solution (HBSS). Brains were immediately extracted and dorsal striatal regions were dissected in ice cold HEPES buffered sucrose buffer (0.32 M sucrose, 4 mM HEPES pH 7.4) containing protease inhibitor cocktail (Roche) and 2mM EDTA. Striatal tissue from 6 mice (3M/3F) was pooled in 10 volumes of HEPES-buffered sucrose and homogenized in a motor driven glass-teflon homogenizer at \~900 rpm (12 strokes). Homogenate was centrifuged at 1000 g at 4°C for 10 min to remove the pelleted nuclear fraction and supernatant was centrifuged at 15,000 g for 15 min to yield the crude synaptosomal pellet. This pellet was resuspended in 1 mL of HEPES-buffered sucrose buffer, layered on top of a discontinuous gradient containing 5mM HEPES and 0.8 to 1.0 to 1.2 M sucrose (top to bottom; equals 27%/34%/41%) in a ultracentrifuge tube, and centrifuged at 150,000 g for 2 hr in a swinging bucket rotor. Synaptosomes were recovered at the interface of 1.0 and 1.2 M sucrose layers, diluted to 0.32 M sucrose by adding 2.5 volumes of 5 mM HEPES pH 7.5 and pelleted by centrifugation at 15,000 g for 20 min.

Immunoblotting and Electron Microscopy {#S18}
--------------------------------------

For immunoblotting, whole brain extracts and synaptosomes were normalized for total protein content using the BCA Assay (Pierce). Following normalization, samples were denatured by the addition of 5 × Laemmli sample buffer (237 mM Tris-HCl, pH 6.8, 10% (wt/vol) SDS, 25% (vol/vol) 2-mercaptoethanol, 25% (vol/vol) glycerol, and 0.056% (wt/vol) bromophenol blue). For AKAP12 blots, aliquots of denatured synaptosomes were boiled for 5 minutes. All samples were resolved by 8%--16% SDS-PAGE, and analyzed by immunoblotting. Antibodies used in this study include anti-DCX (Santa Cruz sc-271390), anti-SV2A (SySy 119002), anti-AKAP12 (Abcam ab49849), anti-Prkacb (Sigma-Aldrich sab2104516), anti GAPDH (CST 2118S), anti-Synaptotagmin (SySy 105011), anti-GluN1 (SySy 114011), anti-VDAC (CST 4661S), anti-Calreticulin (CST 12238S). For electron microscopy, synaptosomes were fixed overnight in 1.25% paraformaldehyde, 2.5% glutaraldehyde, 0.03% picric acid, 0.1M Cacodylate buffer, pH 7.4. Fixed synaptosomes were pelleted and washed in 0.1M cacodylate buffer and postfixed with 1% osmium tetroxide and 1.5% potassium ferrocyanide for 1 hour. Samples were then washed twice in water, once in Maleate buffer (MB) and incubated in 1% uranyl acetate in MB for 1 hr. This was followed by two washes in water and subsequent dehydration for 10 minutes each in the following grades of alcohol: 50%, 70%, 90%, 2×10min 100%. The samples were then placed in propyleneoxide for 1 hr and infiltrated overnight in a 1:1 mixture of propyleneoxide and TAAB Epon (Marivac Canada Inc. St. Laurent, Canada). The following day the samples were embedded in TAAB Epon and polymerized at 60C for 48 hr. Ultrathin sections (about 60 nm) were cut on a Reichert Ultracut-S microtome, transferred to copper grids stained with lead citrate, and visualized in a JEOL 1200EX Transmission electron microscope or a TecnaiG^2^ Spirit BioTWIN. Images were recorded with an AMT 2k CCD camera.

ERLIC separation {#S19}
----------------

Proteomic analysis of striatal synaptosomes was performed by TMTplex experiment using samples of different ages (P8, P12, P14, P18). Each sample contained a pool of dorsal striatal tissue collected from 6 mice (3M/3F) at the different ages. Each sample was submitted for single LC-MS/MS experiment that was performed on a LTQ Orbitrap Elite (Thermo Fischer) equipped with Waters (Milford, MA) NanoAcquity HPLC pump. Peptides were separated onto a 100 μm inner diameter microcapillary trapping column packed first with approximately 5 cm of C18 Reprosil resin (5 μm, 100Å, Dr. Maisch GmbH, Germany) followed by analytical column \~20 cm of Reprosil resin (1.8 μm, 200Å, Dr. Maisch GmbH, Germany). Separation was achieved through applying a gradient from 5%--27% ACN in 0.1% formic acid over 90 min at 200 nL min−1. Electrospray ionization was enabled through applying a voltage of 1.8 kV using a home-made electrode junction at the end of the microcapillary column and sprayed from fused silica pico tips (New Objective, MA). The LTQ Orbitrap Elite was operated in data-dependent mode for the mass spectrometry methods. The mass spectrometry survey scan was performed in the Orbitrap in the range of 395 --1,800 m/z at a resolution of 6 × 104, followed by the selection of the twenty most intense ions (TOP20) for CID-MS2 fragmentation in the Ion trap using a precursor isolation width window of 2 m/z, AGC setting of 10,000, and a maximum ion accumulation of 200 ms. Singly charged ion species were not subjected to CID fragmentation. Normalized collision energy was set to 35 V and an activation time of 10 ms. Ions in a 10 ppm m/z window around ions selected for MS2 were excluded from further selection for fragmentation for 60 s. The same TOP20 ions were subjected to HCD MS2 event in Orbitrap part of the instrument. The fragment ion isolation width was set to 0.7 m/z, AGC was set to 50,000, the maximum ion time was 200 ms, normalized collision energy was set to 27V and an activation time of 1 ms for each HCD MS2 scan.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S20}
=======================================

Analysis of mouse behavior {#S21}
--------------------------

Automated analysis of locomotor behavior was performed in Ethovision XT 11.5 software (Noldus). Wall rearing and grooming behavior was scored manually analyzing the videos offline with observers blinded to genotype. Grooming includes all sequences of face wiping, scratching/rubbing of head and ears, and full-body grooming. Grooming segments less than 3 s apart were considered part of the same grooming bout. For longitudinal characterization of behavior the same animals were analyzed in the open field at different developmental stages. For each developmental time point two 30-minute open field sessions were recorded in consecutive days and results averaged per mouse. All cages and chambers were thoroughly cleaned with Quatricide (Pharmacal Research Labs) and water in between all subjects. Accelerating rotarod test was performed in a different cohort of animals and tested in four consecutive days (P17-P20) with three daily sessions per animal 20--30 minutes apart (4--40rpm in Med Associates ENV-577). Each run was terminated when the animal fell or was unable to maintain locomotion on top of the rotarod (full spin). All experiments described in [Figure 1](#F1){ref-type="fig"} were analyzed using repeated-measures ANOVA across groups with Benferroni multiple comparison test. Behavioral experiments in [Figures 5](#F5){ref-type="fig"} and [S4](#SD1){ref-type="supplementary-material"} were analyzed using unpaired t test. Data for all behavioral experiments are represented per age or experimental group as Mean ± standard error of the mean (SEM). Sample sizes (number of mice per group) and statistical significance for each comparison are indicated in the results section of each individual panel. All statistical tests were performed in GraphPad PRIZM 8 software (GraphPad).

Analysis of electrophysiology data {#S22}
----------------------------------

Detection and analysis of mEPSCs was performed using custom routines in Igor Pro (Wavemetrics) using the following criteria: Minimum amplitude 7pA, Minimum refractory period 2ms, maximum rise/decay separation 4ms, maximum decay tau 20ms, minimum decay tau 0.7 ms, minimum decay time 2ms, minimum rise time 1ms, minimum rise rate 3pA/ms. Frequency and amplitude of mEPSCs were averaged per cell, and further compared using non-parametric Mann Whitney test due to non-Gaussian distribution of values. Plots represented in [Figures 3I](#F3){ref-type="fig"} and [3J](#F3){ref-type="fig"} represent mEPSC frequency and amplitude values of AAV-GFP and AAV-Cre groups normalized to the average of the AAV-GFP group for each developmental time point. Analysis of eEPSC amplitude peak for calculation of PPR in [Figures 3K](#F3){ref-type="fig"} and [3L](#F3){ref-type="fig"} were based on detection of minimum value after 20ms of stimulation subtracted to average baseline 10ms before stimulation. Calculation of input resistance and membrane capacitance in [Figure S3](#SD1){ref-type="supplementary-material"} were performed by fitting evoked currents in response to −5mV voltage steps in the first seconds after break-in. AMPAR oEPSC amplitude peak in [Figure 4](#F4){ref-type="fig"} was determined by calculating the minimum within 20ms after stimulation subtracted to average 50ms baseline prior to optical pulse. NMDAR oEPSC amplitude was determined as value 50ms following optical stimulation. Sample sizes for all electrophysiology experiments (representing number of neurons recorded per group) and statistical significance for each comparison are indicated in the results section of each individual panel. All statistical analyses were done in GraphPad PRIZM 8 software (GraphPad).

Mass spectrometry analysis {#S23}
--------------------------

Raw data were submitted for analysis in Proteome Discoverer 2.1.0.81 (Thermo Scientific) software. Assignment of MS/MS spectra was performed using the Sequest HT algorithm by searching the data against a protein sequence database including all entries from the Human Uniprot database (SwissProt 16,768 and TrEMBL 62,460 total of 79,228 protein forms, 2015) and other known contaminants such as human keratins and common lab contaminants. Sequest HT searches were performed using a 20 ppm precursor ion tolerance and requiring each peptides N-/C termini to adhere with Trypsin protease specificity, while allowing up to two missed cleavages. 6-plex TMT tags on peptide N termini and lysine residues (+229.162932 Da) was set as static modifications while methionine oxidation (+15.99492 Da) was set as variable modification. A MS2 spectra assignment false discovery rate (FDR) of 1% on protein level was achieved by applying the target-decoy database search. Filtering was performed using a Percolator (64bit version) ([@R26]). For quantification, a 0.02 m/z window centered on the theoretical m/z value of each the six reporter ions and the intensity of the signal closest to the theoretical m/z value was recorded. Reporter ion intensities were exported in result file of Proteome Discoverer 2.1 search engine as an excel tables. The total signal intensity across all peptides quantified was summed for each TMT channel, and all intensity values were adjusted to account for potentially uneven TMT labeling and/or sample handling variance for each labeled channel. Statistical significance of protein enrichment changes across development (P8--P18) were determined by analyzing variance of individual peptides across samples (different age) using Friedman test with Benjamini-Hochberg multiple test correction with p \< 0.00134 cutoff in Scaffold 4.5 (Proteome Software). Shank3 showed increased enrichment during P8--18 with p = 0.011 but was included for analysis due to previous validation of increased postnatal expression ([@R59]). Protein expression changes in [Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"} are represented as log~2~ of the max or min abundance values normalized to P8 for proteins with increased or decreased expression across development, respectively. Putative protein-protein interactions of Shank3 and proteins with significant differential enrichment at P8--P18 were analyzed in STRING, GeneMANIA and BioGRID and curated in Cytoscape 3.6. Only data from protein-protein interaction studies were considered as positive interactions. SFARI gene database ([https://gene.sfari.org](https://gene.sfari.org/)) was used to identify ASD risk genes in the identified protein cluster.

DATA AND CODE AVAILABILITY {#S24}
==========================

This study did not generate new code. MATLAB and IgorPro procedures used for analysis of electrophysiology data are available upon request (<rup14@pitt.edu>). The accession number for the mass spectrometry data reported in this paper is MassIVE: MSV000084435.
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![Early Onset of Behavioral Deficits in *Shank3B*^−/−^ Mice\
(A) Total distance traveled for 30 min in the open field test by P21 and P60 WT and *Shank3B*^−/−^ mice. Heatmap represents distance values normalized to P60 WT.\
(B and C) Mean ± SEM of distance traveled by P15--P90 WT and *Shank3B*^−/−^ mice during 30 min (B) in the open field arena or (C) in the center region of the arena.\
(D) Mean ± SEM of fraction of distance traveled in the center versus total arena.\
(E) Mean ± SEM number of wall rearing bouts per session.\
(F) Mean ± SEM total time spent grooming.\
(G) Mean ± SEM duration of individual grooming bouts.\
(H) Mean ± SEM number of grooming bouts per session.\
(I) Mean ± SEM latency to fall in the accelerating rotarod test.](nihms-1542972-f0002){#F1}

![Dynamic Regulation of PKA and ASD Risk Factors during Postnatal Striatal Development\
(A) Electron microscopy images of synaptosomal fractions isolated from mouse dorsal striatum at P8--P18.\
(B) Developmental trajectory of the relative abundance of several proteins associated with synaptic and neural circuit maturation identified by LC-MS/MS.\
(C) Immunoblot analysis of proteins in whole extracts or isolated synaptosome fractions of dorsal striatum from P8--P18 mice.\
(D) Protein-protein interaction network of proteins of striatal synaptosomes with significant abundance change between P8 and P18. The color of the node center represents changes in protein abundance during this period with proteins (red, increased expression; blue, lower expression; log~2~ normalized to P8 levels). Green and orange circles around the nodes label ASD risk factors identified in SFARI gene list or closely related homologs, respectively. Nodes with numbers and letters represent the SFARI gene scoring criteria (1--5, confidence categories; S, syndromic). Edges represent protein-protein interactions pooled from Genemania, STRING, and BioGRID online databases.\
(E) Proteins of striatal synaptosomes with significant change in abundance between P8 and P18 with no known protein-protein interactions. Labeling of nodes similar to that represented in (D).\
(F--I) Normalized relative change in abundance from P8 to P18 of (F) catalytic and regulatory PKA subunits, (G) adenylyl-cyclases, (H) AKAPs, and (I) negative regulators of PKA signaling protein-phosphatase-1 and phosphodiesterases 1B and 10A.](nihms-1542972-f0003){#F2}

![Developmental Switch in SPN Response to Cortical Hyperactivity\
(A) Coronal brain section of *Slc32a1*^*f/f*^ mouse injected with AAV-Cre-EGFP in ACC. Scale bar, 1 mm. CTX, cortex; STR, striatum.\
(B) Whole-cell voltage-clamp recordings in SPNs of DMS in acute brain slices of P14 or P60 *Slc32a1*^*f/f*^ mice injected at P8 with AAV-EGFP (Ctrl) or AAV-Cre-EGFP (Cre) in the ACC.\
(C and D) Mean ± SEM of AMPAR mEPSC frequency (left) and amplitude (right) of (C) P14 or (D) P60 SPNs of *Slc32a1*^*f/f*^ mice injected at P8.\
(E) Experimental diagram depicting whole-cell voltage-clamp recordings in SPNs of DMS in acute brain slices of P21, P28, or P60 *Slc32a1*^*f/f*^ mice injected with AAV-EGFP (Ctrl) or AAV-Cre-EGFP (Cre) 7 days before recordings. Bottom traces are representative mEPSC recordings performed at P21 of mice injected at P15.\
(F--H) Mean ± SEM of AMPAR mEPSC frequency (left) and amplitude (right) of (F) P21, (G) P28, and (H) P60 SPNs of *Slc32a1*^*f/f*^ mice injected 7 days before recordings.\
(I and J) Normalized values of SPN AMPAR (I) mEPSC frequency and (J) mEPSC amplitude of AAV-Cre-injected animals compared to AAV-EGFP controls across development. Note the developmental shift in the change of mEPSC frequency after AAV-Cre-EGFP injections at \~P15.\
(K) Example traces of eEPSCs in SPNs of P60 *Slc32a1*^*f/f*^ mice injected with AAV-EGFP (Ctrl) or AAV-Cre-EGFP (Cre) in response to paired electrical pulses with 50 ms inter-stimulus interval (ISI).\
(L) Mean ± SEM ratio of eEPSC amplitude in response to the two electrical stimuli in (K).](nihms-1542972-f0004){#F3}

![Postnatal Inhibition of PKA Reduces Glutamatergic Synapse Maturation in DMS SPNs\
(A) Coronal brain slice of P15 mouse infected with AAV8-Syn-PKIα-mRuby2 in DMS at P8. The inset shows a magnified view of the striatum with PKIα^+^ and neighboring uninfected (control) SPNs. Scale bar, 1 mm. CTX, cortex; STR, striatum.\
(B) Representative mESPC recordings from DMS control or PKIα^+^ SPNs at P15.\
(C and D) Mean ± SEM (C) mEPSC frequency and (D) mEPSC amplitude in control or PKIα^+^ DMS SPNs.\
(E) Coronal brain slice of P15 Rbp4-Cre;ChR2-EYFP^f/f^ mouse infected with AAV8-Syn-PKIα-mRuby2 in DMS at P8. Scale bar, 1 mm. CTX, cortex; STR, striatum.\
(F) Example AMPAR and NMDAR oEPSCs recorded in control and PKIα^+^ DMS SPNs in response to 1-ms 473 nm light pulses.\
(G) Mean ± SEM. AMPAR oEPSC amplitude in control and PKIα^+^ DMS SPNs.\
(H) Mean ± SEM ratio of NMDAR/AMPAR oEPSC amplitude in control and PKIα^+^ DMS SPNs.](nihms-1542972-f0005){#F4}

![Postnatal Expression of PKIα in DMS Rescues Behavioral Abnormalities in *Shank3B*^−/−^ Mice\
(A) Representative mESPC recordings from control or PKIα^+^ DMS SPNs of *Shank3B*^−/−^ mice at P13.\
(B and C) Mean ± SEM (B) mEPSC frequency and (C) mEPSC amplitude in control or PKIα^+^ DMS SPNs.\
(D) Coronal section of P21 *Shank3B*^−/−^ mouse infected with AAV8-Syn-PKIα-mRuby2 in DMS and ventromedial striatum (VMS) at P8. Scale bar, 1 mm.\
(E) Mean ± SEM total grooming time of P21 *Shank3B*^−/−^ mice expressing GFP or PKIα in the open field.\
(F and G) Mean ± SEM of (F) duration and (G) number of grooming bouts per session.\
(H) The total distance traveled for 20 min in the open field test by P21 *Shank3B*^−/−^ mice injected with AAV-EGFP or AAV-PKIα. Heatmap represents distance normalized to AAV-PKIα.\
(I) Mean ± SEM of total distance traveled in arena.\
(J) Mean ± SEM of the ratio of the distance traveled in the center of the arena over the total distance traveled.\
(K) Mean ± SEM of time spent in the center of the arena.\
(L) Mean ± SEM number of wall rearing bouts per session.](nihms-1542972-f0006){#F5}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                      SOURCE             IDENTIFIER
  ---------------------------------------- ------------------ ------------------------------------
  Antibodies                                                  
  anti-Doublecortin                        Santa Cruz         Cat\# sc-271390, RRID:AB_10610966
  anti-SV2A                                Sysy               Cat\# 119 002, RRID:AB_887802
  Anti-AKAP12                              Abcam              Cat\# ab49849, RRID:AB_2225608
  anti-Prkacb                              Sigma-Aldrich      Cat\# SAB2104516, RRID:AB_10669496
  Anti-GAPDH                               CST                Cat\# 2118, RRID:AB_561053
  anti-Synaptotagmin                       Sysy               Cat\# 105 011, RRID:AB_887832
  anti-GluN1                               Sysy               Cat\# 114 011, RRID:AB_887750
  anti-VDAC                                CST                Cat\# 4661, RRID:AB_10557420
  anti-Calreticulin                        CST                Cat\# 12238, RRID:AB_2688013
  Bacterial and Virus Strains                                 
  AAV8-hSyn-PKI-ires-mRuby                 Yao Chen           <yaochen@wustl.edu>
  AAV9-hSyn-Cre-EGFP                       Penn vector core   AV-9-PV1848
  AAV9-hSyn-EGFP                           Penn vector core   AV-9-PV1696
  Deposited Data                                              
  Mass spectrometry data                                      MassIVE: MSV000084435
  Experimental Models: Organisms/Strains                      
  Ai32(RCL-ChR2(H134R)/EYFP)               JAX                012569
  *Slc32a1*^f/f^                           JAX                012897
  Rbp4-Cre                                 GENSAT             \#RP24--285K21
  pAAV-hSyn-PKI-ires-mRuby                 Yao Chen           <yaochen@wustl.edu>

###### Highlights

-   Early onset of behavioral deficits in *Shank3B*^−/−^ mice during postnatal development

-   Developmental switch in SPN synaptic adaptation to cortical hyperactivity during P15--P21

-   Dynamic regulation of multiple ASD risk factors during striatal synapse maturation

-   PKA inhibition in medial striatal regions ameliorates *Shank3B*^−/−^ behavioral deficits
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